+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia



Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia



Therapeutic Advances in Psychopharmacology 4(6): 257-267



Physicians have prescribed anticholinergic agents such as benztropine, procyclidine, biperiden and trihexyphenidyl for treatment and prophylaxis of antipsychotic-induced extrapyramidal symptoms (EPS) for decades. Anticholinergic agents can however worsen tardive dyskinesia and cause many adverse effects, including cognitive impairment. Previous studies of anticholinergic discontinuation in patients with schizophrenia receiving antipsychotics have yielded a wide range of EPS relapse rates. Improvement in cognition after anticholinergic withdrawal was observed in some studies. This study evaluated the effect of anticholinergic discontinuation on movement disorders, cognition and general psychopathology after a 4-week taper in 20 outpatients with schizophrenia or schizoaffective disorder treated with antipsychotics. Eighteen of twenty patients successfully discontinued their anticholinergic medication; two did not because of akathisia. Repeated measures analysis of variance did not show a significant effect of anticholinergic discontinuation on total Extrapyramidal Symptoms Rating Scale score or on the Parkinsonism, Akathisia, Dystonia or Tardive Dyskinesia subscales. However, significant improvement was found on the Brief Assessment of Cognition in Schizophrenia composite z score at weeks 6, 8 and 12 compared with baseline. Significant improvements were seen on the motor and the symbol-coding tasks. No significant effects were observed on the Positive and Negative Syndrome Scale, Clinical Global Impression - Severity and Clinical Global Impression - Improvement scales. In this 12-week study of anticholinergic discontinuation in 20 outpatients with schizophrenia or schizoaffective disorder, gradual decrease and discontinuation of anticholinergics led to a positive effect on cognition. There were no adverse consequences on general psychopathology and no significant differences for 18 of 20 subjects on movement disorders.

(PDF emailed within 0-6 h: $19.90)

Accession: 057727329

Download citation: RISBibTeXText

PMID: 25489477

DOI: 10.1177/2045125314553611


Related references

Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology 232(9): 1607-1617, 2015

Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. European Child & Adolescent Psychiatry 17(1): 44-53, 2007

The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatrica Scandinavica 136(5): 465-472, 2017

Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study. International Clinical Psychopharmacology, 2017

Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. Journal of Nervous and Mental Disease 199(7): 499-505, 2011

No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. Journal of Clinical Psychopharmacology 33(2): 226-230, 2013

Associations of fatty acids with cognition, psychopathology, and brain-derived neurotrophic factor levels in patients with first-episode schizophrenia and related disorders treated with paliperidone extended release. Journal of Psychopharmacology: 269881117731169-269881117731169, 2017

Psychopathology and cognition in schizophrenia spectrum disorders: The role of depressive symptoms. Schizophrenia Research 39(1): 65-71, Aug 23, 1999

Anticholinergic Burden and Cognition in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2017

Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 35(7): 1753-1764, 2012

Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. International Clinical Psychopharmacology 19(1): 27-29, 2004

Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biological Psychiatry 70(1): 7-12, 2011

Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research 106(2-3): 258-264, 2008

Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophrenia Research 147(1): 132-139, 2013

Decreased plasma levels of gasotransmitter hydrogen sulfide in patients with schizophrenia: correlation with psychopathology and cognition. Psychopharmacology, 2018